K+8

Post-LOE

potassium chloride

Future Genomics Technologies

ANDAORALTABLET, EXTENDED RELEASE

Approved

Jan 1993

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

K+8 (potassium chloride) by Future Genomics Technologies is clinical pharmacology the potassium ion is the principal intracellular cation of most body tissues. Approved for without metabolic alkalosis, digitalis intoxication, hypokalemia in patients. First approved in 1993.

Drug data last refreshed Yesterday

Mechanism of Action

CLINICAL PHARMACOLOGY The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac,…

Worked on K+8 at Future Genomics Technologies? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

K+8

Mechanism of Action

Indications (3)